Relay Therapeutics Gears Up for Investor Engagements This Month
Relay Therapeutics Announces Key Investor Conference Participation
Relay Therapeutics, Inc. (NASDAQ: RLAY), a pioneering company in the field of clinical-stage precision medicine, is gearing up to participate in two significant investor conferences this month. This initiative highlights their commitment to engage with the investment community and share developments related to their groundbreaking therapies aimed at treating cancer and genetic diseases.
Details of Upcoming Conferences
The two investor conferences where Relay Therapeutics' management team will be present include:
Wells Fargo Healthcare Conference
Scheduled for September 4, 2025, this highly anticipated conference offers Relay’s leadership a platform to discuss their innovative strategies and recent advancements. Management will take the stage at 2:15 p.m. ET, presenting insights into their pipeline.
Morgan Stanley 23rd Annual Global Conference
Following closely, Relay will participate in the Morgan Stanley 23rd Annual Global Conference on September 10, 2025, at 11:30 a.m. ET. Here, the company will further delve into its mission and highlight ongoing clinical research efforts focused on the development of its therapies.
Webcast Access and Archival Information
Both fireside chats will be accessible via live stream, allowing investors and interested parties to tune in from anywhere. The webcasts can be found on the Relay Therapeutics website under the Events section. For those unable to attend live, an archive of the presentations will be available for up to 30 days after the events.
About Relay Therapeutics
Relay Therapeutics, known for its cutting-edge Dynamo platform, focuses on redefining precision medicine. This platform uniquely integrates advanced computational methods with experimental approaches to target proteins that have long been challenging to treat. Among their notable projects, the lead asset, RLY-2608, stands out as the first of its kind—a pan-mutant selective PI3K? inhibitor currently undergoing a Phase 3 clinical trial specifically for HR+/HER2- metastatic breast cancer. Moreover, the company is expanding its efforts into PI3K?-driven vascular malformations and developing therapies for NRAS-driven solid tumors and Fabry disease—further enhancing its diverse clinical pipeline.
Contact Information for Further Inquiries
For any additional information, interested parties are encouraged to reach out directly to Pete Rahmer. His contact details are as follows:
Pete Rahmer
Email: prahmer@relaytx.com
Media Relations
For media inquiries, please contact Dan Budwick at 1AB, reachable via phone at 973-271-6085 or through email at dan@1abmedia.com.
Frequently Asked Questions
1. What is Relay Therapeutics' core mission?
Relay Therapeutics is dedicated to developing innovative precision therapies for patients with cancer and genetic disorders.
2. When are the two investor conferences scheduled?
The Wells Fargo Healthcare Conference is set for September 4, 2025, and the Morgan Stanley Global Conference will take place on September 10, 2025.
3. How can I access the webcasts of the conferences?
Webcasts will be available live on Relay Therapeutics' website, and recordings will be accessible for 30 days post-event.
4. What is RLY-2608?
RLY-2608 is Relay Therapeutics' lead clinical asset, a selective PI3K? inhibitor in advanced clinical trials for treating specific breast cancer patients.
5. Who can I contact for more information?
For further details, you can contact Pete Rahmer via email at prahmer@relaytx.com.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
